Technology | July 30, 2012

Emerge Nuclear Software Can Diagnose Appropriate Use

Software can help determine when perfusion imaging is needed, even without obvious symptoms

July 30, 2012 — Emerge Clinical Solutions, a creator of clinical decision support software, announced nuclear myocardial perfusion imaging (MPI) appropriateness update 3.1 that allows for diagnosis of both symptomatic and asymptomatic conditions.

In medicine, patients are simpler to diagnose when they show clear symptoms or signs of disease or injury. However, often an illness is asymptomatic, which means it is present but does not demonstrate obvious symptoms. Asymptomatic patients can be a challenge since asymptomatic illnesses are particularly difficult to discover and diagnose, especially in early stages.

Emerge’s real-time clinical decision solution helps doctors increase diagnosis efficiency and accuracy by filtering comprehensive patient data and history through the company’s rules engine and patented algorithms. The software has been proven to increase identification of certain cardiac diseases by as much as 300 percent. The Emerge rules engine performs more than 8,000 calculations in seconds to help doctors elect the most appropriate testing and procedures and choose a care path.

“Asymptomatic conditions are difficult to uncover, but they are no less threatening to a patient’s health. Emerge’s agnostic software can process data exponentially faster than any human brain, so it helps doctors find the right solution quickly. Time is of the essence when it comes to cardiology, and we help doctors decide the best care path without losing time on unnecessary testing,” said Emerge CEO Scott Finfer.

Cardiologists are often overwhelmed with the volume of information and data to consider when evaluating patients. Emerge’s software simplifies the decision process and merges seamlessly with any electronic medical record (EMR), integrating in real-time. Its algorithms utilize appropriate use criteria and guidelines from the American College of Cardiology (ACC), American Health Association (AHA) and Heart Rhythm Society (HRS). The software exceeds stage 1 meaningful use requirements, as well as the proposed requirements of stages 2 and 3.

For more information: www.emergecds.com

Related Content

MDISS Launches 'WHISTL' Network of Medical Device Security Testing Labs
News | Cybersecurity | August 23, 2017
The Medical Device Innovation, Safety and Security Consortium (MDISS) recently launched the first of more than a dozen...
Sponsored Content | Videos | Information Technology | August 22, 2017
Melissa Martin, MS, president of the American Association of Physicists in Medicine (AAPM), discusses her vision of t
HHS Unveils Improved Web Tool to Highlight Recent Health Information Breaches
News | Cybersecurity | August 21, 2017
The U.S. Department of Health and Human Services (HHS), Office for Civil Rights (OCR) recently launched a revised web...
Enterprise Imaging Growing Its Share of Imaging IT Market
Feature | Enterprise Imaging | August 18, 2017
August 16, 2017 — A new imaging information technology (IT) market report from Signify Research suggests...
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
MaineHealth Selects eUnity Platform for Clinical and Diagnostic Viewing
News | Enterprise Imaging | August 17, 2017
August 17, 2017 — Client Outlook recently announced that MaineHealth has selected eUnity as its...
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
ScImage Awarded U.S. Government DIN-PACS IV Contract
News | PACS | August 16, 2017
ScImage Inc. was recently awarded a new DIN-PACS IV (Digital Imaging Network/Picture Archiving and Communications...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
Neighbors Emergency Center Selects Novarad PACS/RIS
News | PACS | August 15, 2017
August 15, 2017 — Novarad Corp.
Overlay Init